BIODELIVERY SCIENCES INTERNATIONAL INC Form 8-K December 30, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2011 (December 29, 2011)

BioDelivery Sciences International, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-31361 (Commission File Number) 35-2089858 (IRS Employer

Identification No.)


Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

801 Corporate Center Drive, Suite #210

Raleigh, NC 27607 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: 919-582-9050

Not Applicable

(Former name or former address, if changed since last report)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

Item 8.01. Other Information.

On December 29, 2011, BioDelivery Sciences International, Inc. (the Company) issued a press release announcing the Company s response to the announcement by the U.S. Food and Drug Administration that a class-wide Risk Evaluation Mitigation Strategy covering transmucosal fentanyl products has been approved. A copy of such press release is attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release, dated December 29, 2011, announcing the Company s response to the FDA s approval of the class-wide Risk Evaluation Mitigation Strategy for transmucosal fentanyl products.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the Company) related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company s plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, or similar exp statements are based upon the current beliefs and expectations of the Company s management and are subject to significant risks and uncertainties, including those detailed in the Company s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the impact of the TIRF on marketing efforts for, sales of and royalty revenue to BDSI relating to ONSOLIS) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 30, 2011 BIODELIVERY SCIENCES INTERNATIONAL, INC.

By: /s/ James A. McNulty Name: James A. McNulty

Title: Secretary, Treasurer and Chief Financial Officer